Key Speakers
• Peter Adamson, Head of Research, Ophthiris, GlaxoSmithKline
• Riccardo Perfetti, Senior Medical Director, Diabetes & Metabolism Global Franchise, Sanofi-Aventis
• Richard Carr, Senior Director, Merck Sharp & Dohme
• Rafaella Balena, Vice Director of Clinical Science & Leader of Medical Science, F. Hoffmann-La Roche
• Ingrid Warnold, DIRECT Project Leader and Study Delivery Director, AstraZeneca
• Michael Trautmann, Medical Fellow, Global Exanatide Team, Lilly
• Matthew Sheetz, Medical Fellow, Lilly
• Piet Pijper, Global Development Project Leader, Astellas
• Paul Ashton, President & Chief Executive Officer, pSivida
• Stanley Wiegand, Vice President, Ophthalmology and Cardiovascular Research, Regeneron Pharmaceuticals
• Patricia Cole, Executive Director and Head of Imagepace, Medpace
• Didier Pruneau, Head of Scientific Operations, Fovea Pharmaceuticals
• Anne Katrin Sjølie, Chair, DIRECT Programme Steering Committee
• Arnd Gandorfer, Professor of Ophthalmology and Deputy Chairman, University Eye Hospital Munich
• Victor Chong, Consultant Ophthalmologist, University of Oxford
• Adnan Tufail, Consultant Ophthalmologist, Moorfields Eye Hospital
Managing toxic glucose and fat concentrations in the vasculature remain significant challenges for diabetics. As the numbers of patients affected by the disease climbs, so secondary vascular and ophthalmic complications affecting patients continue to grow. With up to 50 million people currently affected by diabetic eye diseases and 100 million forecast by 20251, more effective therapeutics are desperately needed.
Set to double from $32bn to $64bn over the next 15 years2, the global diabetes market is set for stellar growth as changing demographics and new therapies begin entering the clinic.
Focussing on efforts to reduce the burden of hyperglycaemia, dyslipidaemia and retinopathy, Visiongain’s 6th Annual Diabetes conference focuses on the latest developments in this area. We bring you distilled insights from outstanding speakers in key areas including:
• Full market analysis, including medical needs and commercial opportunities
• Novel GLP1 receptor agonists, and SLGT2 and DPP-4 inhibitors
• The use of biomarkers and imaging for the development of novel therapies for diabetes
• New therapeutic targets to reduce cardiovascular disease in type 2 diabetes
• Overcoming microangiopathy and capillary occlusion
• Epidemiology and pharmacotherapies for diabetic eye diseases
• The effects of ACE, RAS and PKC inhibitors on the progression of diabetic retinopathies
• Clinical results from the EUCLID, DIRECT and RASS studies
• New data on intravitreal VEGF and PLGF signalling inhibitors
• Corticosteroid implants to reduce intra-ocular vascular permeability and oedema
• Blockade of the kallikrein-kinin system to treat diabetic retinopathy
Who should attend?
CEOs, Chief Scientific Officers, Chief Operating Officers, Presidents, Senior Vice Presidents, Vice Presidents, Heads, Senior Directors, Directors, Clinicians, Principal Scientists, Principal Investigators, Managers, Project/Team Leaders in:
• Diabetes & Obesity, Clinical R&D
• Endocrinology and Metabolic Diseases
• Cardiovascular and Gastrointestinal Diseases
• Anti-Diabetic Agents & Advanced Diabetes Systems
• Biomarkers
• Imaging and Translational Medicine
• Drug Development
• Ophthalmology, Visual Science and Vision Research
• Retinal Diseases
• Monoclonal Antibodies
• Translational Medicine
• Molecular Neuroscience
• New Products Global Marketing
• Business Development, Licensing & Partnership
• Venture Capital
1Dodson, P.M. (2009). Management of diabetic retinopathy: could lipid-lowering be a worthwhile treatment modality? Eye, 23 (5), pp. 997-1003.
2Visiongain, (2009). World Diabetes Market, 2009-2023.
